S. Nagel

528 total citations
29 papers, 421 citations indexed

About

S. Nagel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, S. Nagel has authored 29 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 4 papers in Epidemiology. Recurrent topics in S. Nagel's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (8 papers). S. Nagel is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (8 papers). S. Nagel collaborates with scholars based in Germany, Switzerland and United Kingdom. S. Nagel's co-authors include Wolfgang Schuette, Thomas Blankenburg, Monika Serke, Christine Lautenschlaeger, K. Hans, Ludwig Fischer von Weikersthal, Angelika Reißig, H Schweisfurth, Aruna Raghavachar and Richard Herrmann and has published in prestigious journals such as Journal of Clinical Oncology, Leukemia and Journal of Thoracic Oncology.

In The Last Decade

S. Nagel

27 papers receiving 404 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Nagel Germany 10 239 207 76 68 50 29 421
Enzo Veltri Italy 10 353 1.5× 150 0.7× 71 0.9× 37 0.5× 57 1.1× 13 421
Gary W. Jean United States 7 239 1.0× 92 0.4× 78 1.0× 80 1.2× 35 0.7× 14 375
Mary‐Anne Kedda Australia 12 145 0.6× 83 0.4× 108 1.4× 38 0.6× 51 1.0× 21 449
Carolyn Quinn United States 6 224 0.9× 183 0.9× 168 2.2× 110 1.6× 54 1.1× 8 505
Annelieke E.C.A.B. Willemsen Netherlands 10 145 0.6× 102 0.5× 89 1.2× 40 0.6× 31 0.6× 25 298
William Koss United States 9 157 0.7× 84 0.4× 139 1.8× 33 0.5× 38 0.8× 19 426
Frank Seebach United States 9 166 0.7× 92 0.4× 106 1.4× 59 0.9× 47 0.9× 37 407
Qingyu Wang China 10 127 0.5× 76 0.4× 47 0.6× 43 0.6× 32 0.6× 48 264
Kazumi Kuriwaki Japan 10 95 0.4× 98 0.5× 127 1.7× 38 0.6× 28 0.6× 22 373
Qiang Su China 11 259 1.1× 177 0.9× 76 1.0× 45 0.7× 64 1.3× 35 454

Countries citing papers authored by S. Nagel

Since Specialization
Citations

This map shows the geographic impact of S. Nagel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Nagel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Nagel more than expected).

Fields of papers citing papers by S. Nagel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Nagel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Nagel. The network helps show where S. Nagel may publish in the future.

Co-authorship network of co-authors of S. Nagel

This figure shows the co-authorship network connecting the top 25 collaborators of S. Nagel. A scholar is included among the top collaborators of S. Nagel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Nagel. S. Nagel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Klughammer, Barbara, Luca Piali, S. Nagel, et al.. (2023). P805 Selnoflast, a potent NLRP3 inhibitor - results from a phase 1b experimental medicine study in patients with Ulcerative Colitis. Journal of Crohn s and Colitis. 17(Supplement_1). i938–i938. 4 indexed citations
2.
Wolf, Robert Christian, Katharina M. Kubera, S. Nagel, et al.. (2019). Vasogenic Brain Edema During Maintenance Hemodialysis. Clinical Neuroradiology. 31(1). 217–224. 9 indexed citations
3.
4.
Herweh, Christian, et al.. (2012). Quantitative High-Field Diffusion Tensor Imaging of Cerebral White Matter in Asymptomatic High-Grade Internal Carotid Artery Stenosis. European Neurology. 67(4). 246–251. 6 indexed citations
5.
Güttler, Felix, Stefan Rakowsky, S. Nagel, Ulf Teichgräber, & P. M. Schlag. (2012). Interdisziplinäre Tumorkonferenzen. Der Onkologe. 18(5). 389–397. 1 indexed citations
6.
Schuette, Wolfgang, S. Nagel, Ludwig Fischer von Weikersthal, et al.. (2011). Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung Cancer: The APRONTA Trial. Journal of Thoracic Oncology. 6(12). 2090–2096. 10 indexed citations
7.
Nagel, S., O Kellner, Walburga Engel-Riedel, et al.. (2011). Addition of Darbepoetin Alfa to Dose-Dense Chemotherapy: Results From a Randomized Phase II Trial in Small-Cell Lung Cancer Patients Receiving Carboplatin Plus Etoposide. Clinical Lung Cancer. 12(1). 62–69. 12 indexed citations
8.
Nagel, S., Martin Sebastian, Stefan Andreas, et al.. (2010). Randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer.. Journal of Clinical Oncology. 28(15_suppl). 7628–7628. 1 indexed citations
9.
Nagel, S., Chia‐Jung Busch, Thomas Blankenburg, & Wolfgang Schütte. (2009). Behandlung der respiratorischen Papillomatose – Kasuistik zur systemischen Therapie mit Bevacizumab. Pneumologie. 63(7). 387–389. 26 indexed citations
10.
Schuette, Wolfgang, et al.. (2009). Docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): The APRONTA trial. Journal of Clinical Oncology. 27(15_suppl). 8047–8047. 2 indexed citations
11.
Nagel, S., Raffaele Califano, Nicholas Thatcher, & Fiona Blackhall. (2007). Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. Expert Opinion on Pharmacotherapy. 8(18). 3265–3275. 11 indexed citations
12.
Herweh, Christian, M. Hartmann, Achim Gass, et al.. (2007). Quantitative diffusion tensor imaging in herpes simplex virus encephalitis. Journal of NeuroVirology. 13(5). 426–432. 11 indexed citations
13.
Nagel, S., et al.. (2007). Évaluation des réadmissions précoces et imprévues passant par le service d'accueil des urgences médicales. Journal Européen des Urgences. 20(1). 145–146. 1 indexed citations
14.
Baka, Sofia, Saifee Mullamitha, Linda Ashcroft, et al.. (2006). Randomized phase III study of carboplatin and paclitaxel versus vincristine, doxorubicin and cyclophosphamide chemotherapy in intermediate and poor prognosis small cell lung cancer: Preliminary results. Journal of Clinical Oncology. 24(18_suppl). 7059–7059. 3 indexed citations
15.
Schuette, Wolfgang, et al.. (2005). Clinical Benefit in NSCLC: Advanced-Stage Patients Require Symptom-Improving Palliation. Experiences from the ‘Iressa’ Expanded Access Program. Oncology Research and Treatment. 28(4). 195–198. 16 indexed citations
16.
Nagel, S., et al.. (2005). Second-line-Behandlung des malignen Pleuramesothelioms mit Pemetrexed (Alimta®) - eine Kasuistik. Pneumologie. 59(2). 108–111. 1 indexed citations
17.
Schuette, Wolfgang, et al.. (2005). Phase II Trial of Gemcitabine/Irinotecan in Refractory or Relapsed Small-Cell Lung Cancer. Clinical Lung Cancer. 7(2). 133–137. 23 indexed citations
18.
Schuette, Wolfgang, S. Nagel, Monika Serke, et al.. (2004). Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: Results of a randomized phase III study. Journal of Clinical Oncology. 22(14_suppl). 7036–7036. 14 indexed citations
19.
Kummerlen, Christine, et al.. (2004). 094 Les fins de vie dans un service des urgences : considérations éthiques après enquête auprès des soignants. Journal Européen des Urgences. 17. 40–40. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Enzo Veltri Breakdown of academic impact, for papers by Gary W. Jean Breakdown of academic impact, for papers by Mary‐Anne Kedda Breakdown of academic impact, for papers by Carolyn Quinn Breakdown of academic impact, for papers by Annelieke E.C.A.B. Willemsen Breakdown of academic impact, for papers by William Koss Breakdown of academic impact, for papers by Frank Seebach Breakdown of academic impact, for papers by Qingyu Wang Breakdown of academic impact, for papers by Kazumi Kuriwaki Breakdown of academic impact, for papers by Qiang Su
Rankless by CCL
2026